Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Targovax","sponsor":"IOVaxis Therapeutics","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Targovax and IOVaxis Therapeutics Enters Option Agreement for TG Mutant RAS Vaccine License and Clinical Development in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"NORWAY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Targovax","sponsor":"IOVaxis Therapeutics","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Targovax Grants IOVaxis 3 Months Extension to the Exclusive License Option for TG Mutant RAS Vaccines in Greater China and Singapore","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"NORWAY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Targovax","sponsor":"Innovation Norway","pharmaFlowCategory":"D","amount":"$0.9 million","upfrontCash":"Undisclosed","newsHeadline":"Innovation Norway Awards NOK 8.2 mn Grant to Targovax for Development of TG Mutant RAS Vaccine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"NORWAY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Targovax","sponsor":"Agenus","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Targovax ASA and Agenus Announce Collaboration on Mutant KRAS Cancer Vaccine Adjuvanted With QS-21 STIMULON\u2122","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"NORWAY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Apricoxib

    Menu

    Apricoxib

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Targovax

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Norway
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Targovax ASA and Agenus Announce Collaboration on Mutant KRAS Cancer Vaccine Adjuvanted With QS-21 STIMULON™

              Details:

              Under the collaboration with Targovax, Agenus will supply QS-21 STIMULON and scientific support for up to three initial TG01 clinical trials in different cancer indications.

              Lead Product(s): Apricoxib,Stimulon

              Therapeutic Area: Oncology Product Name: TG01

              Highest Development Status: Undisclosed Product Type: Vaccine

              Partner/Sponsor/Collaborator: Agenus

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration March 07, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Targovax

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Norway
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Innovation Norway Awards NOK 8.2 mn Grant to Targovax for Development of TG Mutant RAS Vaccine

              Details:

              With the support from Innovation Norway, Targovax has move the TG program forward faster and more broadly, and thus bring benefit to a patient group with poor prognosis and few available treatment options.

              Lead Product(s): Apricoxib,Gemcitabine

              Therapeutic Area: Oncology Product Name: TG01

              Highest Development Status: Phase I/ Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Innovation Norway

              Deal Size: $0.9 million Upfront Cash: Undisclosed

              Deal Type: Funding January 12, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Targovax

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Norway
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Targovax Grants IOVaxis 3 Months Extension to the Exclusive License Option for TG Mutant RAS Vaccines in Greater China and Singapore

              Details:

              Targovax has granted an extension of 3 months to the exclusive option agreement with IOVaxis Therapeutics of Nantong, China, for clinical development and licensing of the Targovax mutant RAS vaccines TG01 and TG02 in China, Hong Kong, Macau and Singapore.

              Lead Product(s): Apricoxib

              Therapeutic Area: Oncology Product Name: TG01

              Highest Development Status: IND Enabling Product Type: Vaccine

              Partner/Sponsor/Collaborator: IOVaxis Therapeutics

              Deal Size: $3.0 million Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement January 06, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Targovax

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Norway
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Targovax and IOVaxis Therapeutics Enters Option Agreement for TG Mutant RAS Vaccine License and Clinical Development in China

              Details:

              Under the agreement, IOVaxis and Targovax will jointly define a development plan in the territory, and IOVaxis will be responsible for all local regulatory filings and will sponsor clinical trials.

              Lead Product(s): Apricoxib

              Therapeutic Area: Oncology Product Name: TG01

              Highest Development Status: Phase I/ Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: IOVaxis Therapeutics

              Deal Size: $100.0 million Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement January 08, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY